Golden Arrow Resources is pleased to report results from the final two holes of the Phase 2 drill program at the San Pietro Copper-Gold-Iron-Cobalt Project. These two holes together with two of the ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

Many materials store information about what has happened to them in a sort of material memory, like wrinkles on a once ...

President Trump's policies, including the national energy emergency decree, aim to keep energy prices low. Read why I remain ...

Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

Vistagen has reported positive outcomes from the exploratory Phase IIA trial of an investigational pherine nasal spray, PH284, for the treatment of cancer cachexia. The 'previously unreported ...

PH284 is our fifth novel investigational pherine, each supported by positive Phase 2 or later clinical data and placebo-like tolerability, underscoring the breadth, diversity and potential of our ...

--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced positive results from an ...

(RTTNews) - Immuneering Corporation (IMRX), a Massachusetts-based biopharmaceutical company Monday announced a positive update from its Phase 2a study of IMM-1-104 combined with modified ...